Drug Profile
Moxidectin - Pfizer
Alternative Names: Milbemycin BLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer; World Health Organization
- Class Anthelmintics; Macrolides; Small molecules
- Mechanism of Action Chloride channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Onchocerciasis
Most Recent Events
- 15 Mar 2019 Medicines Development Limited plans a phase III trial for Onchocerciasis in Congo (PO) (NCT03876262)
- 11 Aug 2011 Discontinued - Phase-III for Onchocerciasis in Congo (PO)
- 11 Aug 2011 Discontinued - Phase-III for Onchocerciasis in Ghana (PO)